Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 47-50

  Lynch, David H ^a   Yang, Xiao Dong ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY ABX; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; DRUG INHIBITION; DRUG RECEPTOR BINDING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

EID: 0036118248     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31522     Document Type: Article

References (4)

1. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
2. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal anti-body, for cancer therapy
3. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
4. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts